PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629234
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629234
Large and Small-scale Bioprocessing Market size was valued at USD 58,950.43 Million in 2023, expanding at a CAGR of 14.60% from 2024 to 2032.
Large-scale and small-scale bioprocessing refer to the different sizes of operations used in the production of biological products, such as pharmaceuticals, biofuels, or food additives, using living organisms or their components. Small-scale bioprocessing typically refers to laboratory or pilot-scale operations where biological products are produced in smaller volumes, often for research and development.
Large and Small-scale Bioprocessing Market- Market Dynamics
Increasing adoption of biomanufacturing and rising demand from biopharmaceuticals & bioreactor systems are expected to propel market demand
The most significant driver of the bioprocessing market, particularly in large-scale operations, is the increasing demand for biopharmaceuticals. The global pharmaceutical industry is shifting towards biologics such as monoclonal antibodies, vaccines, gene therapies, and recombinant proteins. These products are often produced through complex bioprocesses, including fermentation and cell culture techniques, which require large-scale facilities. The aging global population and the rise in chronic diseases such as cancer, diabetes, and cardiovascular diseases are pushing the demand for biopharmaceutical products. Advancements in biotechnology and genetic engineering are propelling both small and large-scale bioprocessing markets. Innovations such as CRISPR gene editing, synthetic biology, and recombinant DNA technology have revolutionized the development of genetically modified organisms (GMOs) used in production.
The trend toward biomanufacturing is also a key factor driving market growth. Biomanufacturing refers to the production of biological products using living cells or microorganisms. Large-scale bioprocessing benefits from this trend as the pharmaceutical industry moves away from chemical synthesis to biological production methods, which are considered more sustainable and environmentally friendly. As manufacturing processes become more automated and controlled, large-scale bioreactors and fermentation systems are being used to meet the increasing demand for biopharmaceuticals. The recent development of bioreactor systems both Large and Small has played a major role in the expansion of the bioprocessing market. Advanced bioreactors with better controls for temperature, pH, oxygen, and nutrient flow allow for more precise and efficient production.
Large and Small-scale Bioprocessing Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 14.60% over the forecast period (2024-2032)
Based on Workflow Type segmentation, the downstream processing segment was predicted to show maximum market share in the year 2023, owing to its better product purification in processing.
Based on Product segmentation, the bioreactors segment was the leading Product in 2023, due to soaring demand for bioreactor & accessories from the biotech sector.
Based on Mode segmentation, the in-house segment was the leading Mode segment in 2023, due to high penetration of large-scale market players.
On the basis of region, North America was the leading revenue generator in 2023, owing to growing R&D in biomanufacturing.
The Global Large and Small-scale Bioprocessing Market is segmented on the basis of Workflow Type, Product, Mode, and Region.
The market is divided into three categories based on Workflow Type: downstream processing, fermentation, and upstream processing. The downstream processing segment dominates the market. The growing demand from bioprocessing engineering and advancement in production processing is enhancing market growth.
The market is divided into five categories based on the Product: bioreactors, filtration assemblies, bioreactor accessories, bags & containers, and others. The bioreactors segment is expected to grow at the fastest CAGR over the forecast period, owing to the increasing trend of automated cell culturing.
The market is divided into two categories based on Mode: in-house and outsourced. The in-house segment dominates the market and is expected to maintain its high dominance during the forecast period. The increasing demand from in-house biopharmaceutical production & biologics is anticipated to expand market growth.
Large and Small-scale Bioprocessing Market- Geographical Insights
Worldwide, the Large and Small-scale Bioprocessing market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America holds the largest market share due to well-established biopharma companies and strong investment in R&D. The U.S. dominates this region, with key players focusing on innovative therapeutics such as monoclonal antibodies, vaccines, and cell therapies. Europe is the second-largest market, led by Germany, the UK, and France. There is increasing use of bioprocessing for bio-based chemicals and pharmaceuticals. Asia Pacific is the fastest-growing market driven by China, India, Japan, and South Korea. Surge in biological production facilities and growing adoption of single-use technologies.
The Large and Small-scale Bioprocessing market is moderately competitive in nature. The market is shaped by several key players and notable developments driven by technological advancements, strategic expansions, and partnerships. Key industry participants include Merck KGaA, Sartorius AG, Thermo Fisher Scientific, GE Healthcare (including its subsidiary Cytiva), Lonza Group, Boehringer Ingelheim, Danaher Corporation, and Fujifilm Diosynth Biotechnologies. These companies dominate the market through innovations in bioprocessing technologies and robust global footprints. Single-use technologies are a significant growth driver, with companies like Sartorius AG and Thermo Fisher Scientific expanding their portfolios in this area to enhance efficiency and flexibility in bioprocessing.
In 2023, Sartorius AG acquired Polyplus for around USD 2.6 billion to enhance its capabilities in gene and cell therapies.
In 2023, Merck KGaA invested USD 105 million in its China facility to boost single-use manufacturing capabilities.